NCT00576069View on ClinicalTrials.gov

Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

RecruitingOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

October 25, 2007

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Asthma
Interventions
DRUG

budesonide/formoterol

2 inhalations 2X/daily in treated arm/group. No placebo group

DRUG

fluticasone/salmeterol

fluticasone 100ug/salmeterol 50ug, 1 inhalation bid noplacebo fluticasone 250ug/salmeterol 50ug, 1 inhalations bid no placebo Spiriva handihaler daily or respihaler 2 inhalations daily no placebo group

DRUG

mometasone/formoterol

"200/5 mcg two puffs bid 100/5 mcg two puffs bid Breo Ellipta once daily Spiriva capsule handihaler once daily or Spiriva respihaler 2 in~no placebo group"

DRUG

Prednisone

0-15 mg daily as needed

Trial Locations (1)

90712

RECRUITING

Arthur F Gelb Medical Corporation, Lakewood

All Listed Sponsors
lead

Gelb, Arthur F., M.D.

INDIV